Skip to main content
SpringerLink
Log in
Book cover

The Kidney and Hypertension in Diabetes Mellitus pp 409–418Cite as

Clinical Trials in Overt Diabetic Nephropathy

  • Chapter

  • 106 Accesses

Zusammenfassung

There is accumulating data available regarding how overt diabetic nephropathy should be treated to arrest the progressive decline in renalfunction. Some interventions are controversial but improved metabolic control is getting increasing acceptance as a way to improve prognosis also during this stage. There is agreement on that antihypertensive treatment should be aggressive and metaanalyses indicate that ACE-inhibitors offers an advantage. In non-diabetic renal disease intensive antihypertensive treatment adds only little benefit[1]. In contrast to this, several studies have shown that aggressive antihypertensive treatment is probably the most important factor to determine the rate of decline in kidney function in diabetic nephropathy. There are no controlled studies with different target blood pressure in different groups such as in non diabetic renal disease [1]. The evidence that antihypertensive treatment can preserve renal function comes from studies showing a much reduced rate of renal disease progression after effective blood pressure control [2,3]. These studies compare the rate of decline in glomerular filtration rate during intervention with retrospective data which is not ideal since uncontrolled factors might influence the outcome. However, the effect of antihypertensive treatment is so profound that anyone that treats these patients observe that end-stage renal failure is postponed by antihypertensive treatment and that the disease runs an accelerated course during uncontrolled hypertension.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G. The effect of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med 1993; 30: 877–874.

    Google Scholar 

  2. Parving H-H, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen PA. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J 294: 1443–1447,1987.

    Article  CAS  Google Scholar 

  3. Mogensen CE. Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment. Scand J Clin Lab Invest 1976; 36:383–388.

    Article  PubMed  CAS  Google Scholar 

  4. Björck S, Nyberg G, Mulec H, Graneros G, Herlitz H, Aurell M:Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J 1986; 293:467–470.

    Article  Google Scholar 

  5. Tagnma Y, Kitamoto Y, Futaki G, Ueda H, Monma H, Ishizaki M, Takahashi H, Sekino H, Sasaki Y: Effect of Captopril on heavy proteinuria in azotemic diabetics. N Engl J Med 1985, 313:1617–1620.

    Article  Google Scholar 

  6. Rudberg S, Aperia A, Freyschuss U, Persson B. Enalapril reduces microalbuminuria in young normotensive type 1 (insulin-dependent) diabetic patients irrespective of its hypotensive effect. Diabetologia 1990; 33: 470–476.

    Article  PubMed  CAS  Google Scholar 

  7. Elving LD, Wetzels JFM, de Nobel E, Hoitsma AJ, Berden JHM. Captopril acutely lowers albuminuria in normotensive patients with diabetic nephropathy. Am J Kidney Dis 1992; 20: 559–563.

    PubMed  CAS  Google Scholar 

  8. Bakris GL, Bamhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection, Kidney Int 1992; 41: 912–919.

    Article  PubMed  CAS  Google Scholar 

  9. Holdaas H, Hartmann A, Lien MG, Nilsen L, Jervell J, Fachald P, Endresen L, Djseland O, Berg KJ. Contrasting effects of lisinopril and nifedipine on albuminuria and tubular transport functions in insulin dependent diabetics with nephropathy. J Int Med 1991; 229:163–170.

    Article  CAS  Google Scholar 

  10. Gansevoort RT, Apperloo AJ, Heeg JE, De Jong PE, De Zeeuw D. The antiproteinuric effect of antihypertensive agents in diabetic nephropathy. Arch Int Med 1992; 152: 2137–2138.

    Article  CAS  Google Scholar 

  11. Björck S, Mulec H, Johnsen SA, Norden G, Aurell M Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992; 304: 339–343.

    Article  PubMed  Google Scholar 

  12. Stornello M, Valvo EV, Scapellato L. Comparative effects of enalapril, atenolol and chlorothalidone on blood pressure and kidney function of diabetic patients affected by arterial hypertension and persistent proteinuria. Nephron 1991; 58: 52–57.

    Article  PubMed  CAS  Google Scholar 

  13. Maki DD, Ma JZ, Louis TA, Kasiske BL. Long-term of antihypertensive agents on proteinuria and renal function 1995, 155:1073–1080.

    CAS  Google Scholar 

  14. Weidmann P, Schneider M, Böhlen L. Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: an updated metaanalysis. Nephrol Dial Transplant 1995; 10(suppl 9): 39–45.

    PubMed  Google Scholar 

  15. Mulec H, Johnsen S-A, Carlström J, Björck S. Intial decrease in proteinuria after institution of ACE inhibitor treatment predicts long-term prognosis for kidney function in overt diabet neph. san antonio. J Am Soc Nephrol 1997; 8: 116A

    Google Scholar 

  16. Mulec H, Johnsen S-A, Björck S. Long-term enalapril treatment in diabetic nephropathy. Kidney Int 1994; 45 (suppl 45): S-141-S-144.

    Google Scholar 

  17. Parving H-H, Hommel E, Smidt UM. Protection of kidney function and decrease in albuminuria by Captopril in insulin dependent diabetics with nephropathy. Br Med J; 1988 297:1086–1091.

    Article  Google Scholar 

  18. Ferder L Daccordi H, Panzalis M, Inserra F. Angiotensin converting enzyme inhibitors versus calcium antagonists in the treatment of diabetic hypertensive patients. Hypertension 1992; 19 (suppl. 2): II-237-II-242.

    Google Scholar 

  19. Ravid M, Savin H, Jutrin I, Boitai T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normoten-sivetype II diabetic patients. Ann Int Med 1993; 118:577–581.

    Article  PubMed  CAS  Google Scholar 

  20. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456–1462

    Article  PubMed  CAS  Google Scholar 

  21. Mogensen CE, Keane WF, Bennet PH, Jerums G, Parving H-H, Passa P, Steffes MW, Striker GE, Viberti GC. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995; 346:1080–4.

    Article  PubMed  CAS  Google Scholar 

  22. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977–86.

    Article  Google Scholar 

  23. Microalbuminuria collaborative study group: Intensive therapy and progression to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria. BMJ 1995; 311:973–7.

    Article  Google Scholar 

  24. Krolewski AS, LMB Lafel, Krolewski M, Quinn M and Warram JH. Glycosylated haemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med 1995; 332:1251–5.

    Article  PubMed  CAS  Google Scholar 

  25. H-H, Rossing P, Hommel H, Smidt UM. Angiotensin converting enzyme inhibition in diabetic nephropathy: Ten years experience. Am J Kidney Dis 1995; 26:99–107.

    Article  PubMed  Google Scholar 

  26. Breyer JA, Bain RP, Evans JK, Nahman NS, Lewis E, Cooper M, McGill J, Berl T, and the collaborative study group: Predictors of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. Kidney Int 1996; 50:1651–1658.

    Article  PubMed  CAS  Google Scholar 

  27. Gerstoft J, Balslov JT, Brahm M, Brun C, Jrgensen F, Jrgensen HE, Larsen M, Larsen S, Lorenzen I, Lober M, Thomsen AC. Prognosis in glomerulonephritis. II. Regression analysis of prognostic factors affecting the course of renal function and the mortality in 395 patients. Calculation of a prognostic model. Report from a Copenhagen study group of renal diseases. Acta Med Scand 1986; 219: 179–187.

    Article  PubMed  CAS  Google Scholar 

  28. Mulec H, Johnsen SA, Björck S. Cholesterol — A renal risk factor in diabetic nephropathy? Am J Kidney Disease 1993; 22: 196–201.

    CAS  Google Scholar 

  29. Hommel E, Andersen P, Gal M-A, Nielsen F, Jensen B, Rossing P, Dyerberg J, Parving H-H. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia 1992; 35: 447–451.

    Article  PubMed  CAS  Google Scholar 

  30. Nielsen S, Schmitz O, Moller N, Porksen N, Klausen IC, Alberti KG, Mogensen CE. Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 1993; 36(10): 1079–86

    Article  PubMed  CAS  Google Scholar 

  31. Lam KSL, Cheng IKP, Janus ED, Pang RWC. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995; 38: 604–609.

    Article  PubMed  CAS  Google Scholar 

  32. Ravid M, Neuman L, Lishner M. Plasmalipids and the progression of nephropathy in diabetes mellitus type II: Effect of ACE inhibitors. Kidney Int 1995; 47: 907–910.

    Article  PubMed  CAS  Google Scholar 

  33. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S):Diabetes Care 1997; 20: 614–20

    PubMed  CAS  Google Scholar 

  34. Mulec H, Blohmé G, Kullenberg K, Nyberg G, Björck S. Latent overhydration and nocturnal hypertension in diabetic nephropathy. Diabetologia 1995; 38: 216–220.

    Article  PubMed  CAS  Google Scholar 

  35. Norden G, Björck S, Granérus G, Nyberg G: Renal function estimation in diabetic nephropathy -evaluation of five methods. Transplantation proceedings 1986; 18: 1645–1646.

    Google Scholar 

  36. Heeg JE, De Jong PE, van der Hem GK, de Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989; 36: 272–279.

    Article  PubMed  CAS  Google Scholar 

  37. Mulec H, Blohmé G, Grände B, Björck S. The Effect of Metabolic Control on Rate of Decline in Renal Function in Insulin Dependent Diabetes Mellitus with Overt Diabetic Nephropathy. Nephrol Dial Transplant in press.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Njurmottagningen, Sahlgrenska Sjukhuset, Göteborg, Sweden

    Staffan Björck

Authors
  1. Staffan Björck
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medical Department M (Diabetes & Endocrinology), Aarhus Kommunehospital, Aarhus University Hospital, Aarhus C, Denmark

    Carl Erik Mogensen

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Björck, S. (1998). Clinical Trials in Overt Diabetic Nephropathy. In: Mogensen, C.E. (eds) The Kidney and Hypertension in Diabetes Mellitus. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-6752-0_41

Download citation

  • DOI: https://doi.org/10.1007/978-1-4757-6752-0_41

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4757-6754-4

  • Online ISBN: 978-1-4757-6752-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation